Evidence map›Paper›PMID 33556628›Full record

ArticleNew biotechnology2021

FN3-based monobodies selective for the receptor binding domain of the SARS-CoV-2 spike protein.

Christina J Miller, Jennifer E McGinnis, Michael J Martinez, Guangli Wang, Jian Zhou, Erica Simmons, Tohti Amet, Sanofar J Abdeen, James W Van Huysse, Ronald R Bowsher and 1 more

Open access · greenAbstract read
In one paragraph

Article in New biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Christina J MillerTango Biosciences, Inc., 2201 W. Campbell Park Drive, Chicago, IL 60612 USA.
Jennifer E McGinnisTango Biosciences, Inc., 2201 W. Campbell Park Drive, Chicago, IL 60612 USA.
Michael J MartinezTango Biosciences, Inc., 2201 W. Campbell Park Drive, Chicago, IL 60612 USA.
Guangli WangEuprotein Inc., 675 US Highway 1, Suite 129, North Brunswick, NJ 08902 USA.
Jian ZhouLifeTein LLC, 100 Randolph Road, Suite 2D, Somerset, NJ 08873 USA.
Erica SimmonsB2S Life Sciences, 97 East Monroe Street, Franklin, IN 46131 USA.
Tohti AmetB2S Life Sciences, 97 East Monroe Street, Franklin, IN 46131 USA.
Sanofar J AbdeenB2S Life Sciences, 97 East Monroe Street, Franklin, IN 46131 USA.
James W Van HuysseB2S Life Sciences, 97 East Monroe Street, Franklin, IN 46131 USA.
Ronald R BowsherB2S Life Sciences, 97 East Monroe Street, Franklin, IN 46131 USA.
Brian K KayTango Biosciences, Inc., 2201 W. Campbell Park Drive, Chicago, IL 60612 USA. Electronic address: bkay@tangobio.com.
Tango Therapeutics (United States) · US

Funding

Array Based Affinity SelectionR41GM134782 · NIGMS · TANGO BIOSCIENCES, INC. · PI KAY, BRIAN KENNETH · 2019 to 2020
$407k
NIAID NIH HHS HHSN272201400008CNIGMS NIH HHS R41 GM134782
6 · The paper itself

Abstract

A phage library displaying 10

Indexed as

Antibody SpecificityAngiotensin-Converting Enzyme 2Cell LineCross ReactionsEpitopesHumansProtein DomainsSARS-CoV-2Single-Chain AntibodiesSpike Glycoprotein, CoronavirusACE2 protein, humanAngiotensin-Converting Enzyme 2EpitopesSingle-Chain AntibodiesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Affinity selectionAngiotensin-converting enzymeCoronavirusMonobodyPhage-displayReceptorSARS-CoV-1 virusSARS-CoV-2 virusSpike protein

Identifiers

PMID33556628
PMCPMC7863792
OpenAlexW3129005836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.